Sanofi Pasteur Licenses Dengue Vaccine Technology from Maxygen
Maxygen, Inc. (Redwood City, CA), has announced the licensing of its proprietary dengue virus antigen technology to Sanofi Pasteur (Lyon, France).
Maxygen, Inc. (Redwood City, CA), has announced the licensing of its proprietary dengue virus antigen technology to Sanofi Pasteur (Lyon, France). Under the terms of the agreement, Maxygen will transfer to Sanofi Pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second-generation vaccine. The deal could be worth up to $24.5 million for Maxygen. Sanofi Pasteur had recently presented positive results for their tetravalent dengue vaccine candidate after Phase 2 trials using Acambis technology.
The dengue virus is a mosquito-borne pathogen that infects over 50 million people each year, causing 500,000 hospitalizations, according to the World Health Organization.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
